ArticleRSC advances2026
Theacrine-rich Jianghua Kucha black tea alleviates depression
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Jianghua Kucha black tea (JH), a distinct variety characterized by its high theacrine content, exhibits significant antidepressant potential, however, bridging its systemic metabolic benefits to specific molecular targets remains a major challenge. In this study, we integrated untargeted serum metabolomics with multi-scale computational biology to explore the potential mechanism of action of JH in a chronic unpredictable mild stress (CUMS) mouse model. Rather than acting through a single pathway, metabolomic profiling revealed that JH induced a comprehensive reprogramming of the circulatory metabolic landscape. Specifically, JH attenuated the metabolic perturbations associated with the maladaptive shunting of tryptophan toward the kynurenine pathway, thereby favoring the restoration of serotonin (5-HT) biosynthesis precursors. To elucidate the molecular drivers behind this metabolic shift, integrative network pharmacology and atomistic molecular dynamics (MD) simulations were employed, prioritizing TPH1 as a high potential therapeutic target. The computational models predicted that JH's characteristic bioactives, notably theacrine and theaflavins, could form stable, high-affinity binding conformations with TPH1. Collectively, this study provides a novel "metabolism-target" structural framework, providing theoretical insights into the circulatory mechanisms of JH and highlighting its significant promise as a dietary intervention for mood disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.